Graeme Eisenhofer1, Mirko Peitzsch2, Denise Kaden2, Katharina Langton2, Anastasios Mangelis2, Christina Pamporaki3, Jimmy Masjkur3, Aikaterini Geroula3, Max Kurlbaum4, Timo Deutschbein4, Felix Beuschlein5, Aleksander Prejbisz6, Stefan R Bornstein3, Jacques W M Lenders7. 1. Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. Electronic address: Graeme.Eisenhofer@uniklinikum-dresden.de. 2. Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. 3. Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany. 4. Department of Internal Medicine, Division of Endocrinology, University Hospital, University of Würzburg, Würzburg, Germany. 5. Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany; Klinik für Endokrinologie, Diabetologie und Klinische Ernährung, Universitätsspital Zürich, Zürich, Switzerland. 6. Department of Hypertension, Institute of Cardiology, Warsaw, Poland. 7. Department of Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
Abstract
BACKGROUND: Plasma or urinary metanephrines are recommended for screening of pheochromocytomas and paragangliomas (PPGLs). Measurements of urinary free rather than deconjugated metanephrines and additional measurements of methoxytyramine represent other developments. For all measurements there is need for reference intervals. METHODS: Plasma free, urinary free and urinary deconjugated O-methylated catecholamine metabolites were measured by LC-MS/MS in specimens from 590 hypertensives and normotensives. Reference intervals were optimized using data from 2,056 patients tested for PPGLs. RESULTS: Multivariate analyses, correcting for age and body surface area, indicated higher plasma and urinary metanephrine in males than females and sex differences in urinary normetanephrine and free methoxytyramine that largely reflected body size variation. There were positive associations of age with plasma metabolites, but negative relationships with urinary free metanephrine and methoxytyramine. Plasma and urinary normetanephrine were higher in hypertensives than normotensives, but differences were small. Optimization of reference intervals using the data from patients tested for PPGLs indicated that age was the most important consideration for plasma normetanephrine and sex most practical for urinary metabolites. CONCLUSION: This study clarifies impacts of demographic and anthropometric variables on catecholamine metabolites, verifies use of age-specific reference intervals for plasma normetanephrine and establishes sex-specific reference intervals for urinary metabolites.
BACKGROUND: Plasma or urinary metanephrines are recommended for screening of pheochromocytomas and paragangliomas (PPGLs). Measurements of urinary free rather than deconjugated metanephrines and additional measurements of methoxytyramine represent other developments. For all measurements there is need for reference intervals. METHODS: Plasma free, urinary free and urinary deconjugated O-methylated catecholamine metabolites were measured by LC-MS/MS in specimens from 590 hypertensives and normotensives. Reference intervals were optimized using data from 2,056 patients tested for PPGLs. RESULTS: Multivariate analyses, correcting for age and body surface area, indicated higher plasma and urinary metanephrine in males than females and sex differences in urinary normetanephrine and free methoxytyramine that largely reflected body size variation. There were positive associations of age with plasma metabolites, but negative relationships with urinary free metanephrine and methoxytyramine. Plasma and urinary normetanephrine were higher in hypertensives than normotensives, but differences were small. Optimization of reference intervals using the data from patients tested for PPGLs indicated that age was the most important consideration for plasma normetanephrine and sex most practical for urinary metabolites. CONCLUSION: This study clarifies impacts of demographic and anthropometric variables on catecholamine metabolites, verifies use of age-specific reference intervals for plasma normetanephrine and establishes sex-specific reference intervals for urinary metabolites.
Authors: Minghao Li; Christina Pamporaki; Stephanie M J Fliedner; Henri J L M Timmers; Svenja Nölting; Felix Beuschlein; Aleksander Prejbisz; Hanna Remde; Mercedes Robledo; Stefan R Bornstein; Jacques W M Lenders; Graeme Eisenhofer; Nicole Bechmann Journal: Discov Oncol Date: 2021-03-19
Authors: Susan Richter; Bei Qiu; Mirthe Ghering; Carola Kunath; Georgiana Constantinescu; Charlotte Luths; Christina Pamporaki; Nicole Bechmann; Leah Meuter; Aleksandra Kwapiszewska; Timo Deutschbein; Svenja Nölting; Mirko Peitzsch; Mercedes Robledo; Aleksander Prejbisz; Karel Pacak; Volker Gudziol; Henri J L M Timmers; Graeme Eisenhofer Journal: Endocr Relat Cancer Date: 2022-03-21 Impact factor: 5.678
Authors: Karin Eijkelenkamp; Thamara E Osinga; Martijn van Faassen; Ido P Kema; Michiel N Kerstens; Karel Pacak; Wim J Sluiter; Thera P Links; Anouk N A van der Horst-Schrivers Journal: Clin Chem Date: 2021-08-05 Impact factor: 12.167
Authors: Martijn van Faassen; Rainer Bischoff; Karin Eijkelenkamp; Wilhelmina H A de Jong; Claude P van der Ley; Ido P Kema Journal: Anal Chem Date: 2020-06-12 Impact factor: 6.986